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Summary 
Antibodies directed against the autoantigen p26  were detected in sera from 32 patients with 
acute Epstein-Barr virus (EBV) infection and clinical  symptoms of infectious mononucleosis. 
P26  has now been identified as  the  enzyme manganese superoxide dismutase (MnSOD)  by 
comparison of the NHz-terminal amino acid sequence.  Antibodies against MnSOD belong to 
the immunoglobulin class M. They are not detectable in sera of patients with other herpesvirus 
infections. In the 32 patients investigated, the rise and fall of the autoantibodies coincides with 
the clinical symptoms. In vitro, the autoantibodies were shown to inhibit the dismutation of 
superoxide radicals by blocking MnSOD. As presented in the discussion this effect may contribute 
to the pathogenesis of acute EBV infection. 
cute Epstein-Barr virus (EBV) infection becomes apparent 
with the clinical  picture of infectious mononucleosis 
(IM). Due to its B lymphotropism, EBV is not only capa- 
ble of infecting and immortalizing B cells, but is also ca- 
pable of activating resting B cells, which leads to the pro- 
duction of antibodies of various specifidties including heterophil 
antibodies, cold agglutinins against blood group antigens, 
as well as antibodies reacting with the cytoskeleton, and nu- 
clear antigens (1). We discovered two autoantibodies against 
the cellular antigens p26 and p29 (2). The antigen p29 was 
identified  as  human  triosephosphate  isomerase  (TPI)  as 
presented previously (3). Anti-TPI was shown to be a causa- 
tive agent for hemolysis, which is a complication of acute 
EBV infection (4,  5).  With a new approach, we were able 
to identify the autoantigen p26  as  manganese superoxide 
dismutase (MnSOD). 
Materials and Methods 
Sera.  Sera  from 32 patients with acute EBV infections and sera 
from 25 patients with other herpesvirus  infections  were investigated 
(10 acute varicella-zoster infections, 9 cytomegalovirus infections, 
6 herpes simplex virus infections). Sera from 50 healthy volunteers 
were tested as controls. 
Preparing the Antigens.  Various  EBV genome positive and nega- 
tive lymphoblastoid cell lines (0.1 ml packed volume) were re- 
suspended in equal volumes of lysis buffer (6) containing 9.5 M 
urea, 2% (wt/vol) NP-40, and 5% ~-mercaptoethanol; further dis- 
integration was achieved by five cycles of freezing and thawing 
(-25~  temperature). The cell lysates were centrifuged at 
10,000 g for 5 min. The supernatant fluid was used for antigen 
preparation by SDS-PAGE followed by immunoblotting. 
PAGE.  Composition and electrophoresis  ofSDS-13% (wt/vol) 
polyacrylamide slab gels were carried out as described by Heer- 
mann et al. (7). The electrotransfer of proteins from SDS gels to 
polyvinylidenedifluoride  (PVDF) membranes (Millipore  Continental 
Water Systems, Bedford, MA) was performed by transversal elec- 
trophoresis (8). Nonreducing SDS-PAGE was carried out using the 
method of Maurer (9) with minor modifications. Staining of the 
SDS-polyacrylamide  gels was done with Coomassie blue or silver 
salts (10). 
Isolation and Purification of p26.  p26 was isolated from a Raji 
cell lysate by means of electroelution (11) after preparative SDS- 
13% PAGE. After further purification on SDS-10-18% gradient 
polyacrylamide gel, the electrotransfer on PVDF for protein se- 
quencing was performed. 
Immunostaining of the Blots.  Horseradish  peroxidase-conjugated 
antibodies specific for Ig/H and Ig/L chains (DAKO, Glostrup, 
Denmark)  were used in a dilution  of 1:1,000 in  PBS  (2 mM 
KH2PO4, 180 mM NaC1, 9 mM Na2HPO4-2 H20, pH 7.2), con- 
taining 20%  (vol/vol) fetal calf serum. 
A~nity Purification of Anti-MnSOD Antibodies.  Purification of 
autoantibodies  was performed  as described for anti-TPI  antibodies (12). 
Incomplete Proteolytic Cleavage of  p26.  Purified  p26 was cleaved 
with endoproteinase  Glu-C (Protease V 8) from Staphylococcus  aureus 
V8 (Boehringer Mannheim, Mannheim, Germany) according to 
the method of Houmard and Drapeau (13). However, cleavage  of 
p26 was not completed to gain fragments of a sufficient size to 
be recognized  in immunoblot of IM sera after SDS-PAGE separation. 
Determination of Amino Acid Sequence.  To determine the NH2- 
terminal amino acid sequence, an automatic gas phase sequencer 
(model 470 A; Applied Biosystems, Inc., Foster City, CA) was 
used (14). The amino acid sequence obtained was compared with 
data of the protein sequence databases of the Martinsried Institute 
for Protein Sequences (Martinsried, Germany) and the  Protein 
Identification Resource (Atlanta, GA). 
Isolation of MnSOD from Liver Tissue.  MnSOD was purified 
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a patient who did not have neoplastic or hepatic diseases according 
to the procedure described by Matsuda et al. (15). Activity was 
visualized on 10% polyacrylamide  gels under nondenaturing con- 
ditions (16). 
Inhibition of the Enzyme Activity of  MnSOD In Vitro by Antibodies 
against p26 (MnSOD).  The inhibitory activity of anti-MnSOD 
antibodies in MnSOD was determined by applying the method 
Yoshida and Miwa (17) used for phosphoglycerate kinase. Briefly, 
the autoantibodies  were adjusted to 2 #g/ml in 0.15 M NaC1. 20 #1 
MnSOD (833.5 nkat/ml) were added to 50 #1 antibody solution 
(0.2/~g/ml).  After incubation for 18 h at 4~  the MnSOD ac- 
tivity was measured using the optic assay described by McCord 
and Fridovich (18). Each assay was done in quadruplicate. 
Results 
The IgM-fraction from sera of patients with IM reacted 
with lymphoblastoid cell lines and primary lymphocytes, and 
was exhibited as a weak granular cytoplasmatic fluorescence, 
which was more dense around the nucleus than in the pe- 
riphery. To identify the cellular antigens, various types of 
human lymphocytes including Raft cells were lysed. The ly- 
sates were separated  in SDS-PAGE. After electrotransfer on 
a PVDF membrane, the lysates were used for immune reac- 
tions with patients' sera.  Two major antigens were recog- 
nized in all cell lysates. In Fig. 1, four examples of the typical 
reaction of sera from the acute phase of an acute EBV infec- 
tion on a Raji cell lysate are shown.  IgM antibodies react 
with two proteins of a molecular mass of 26  (p26)  and 29 
kD (p29),  respectively.  We had previously identified p29 as 
TPI. IgM antibodies to p26/p29 (TPI) were not detected in 
the sera of healthy probands or of patients with acute herpes 
simplex virus or variceUa-zoster  virus infections. Only a weakly 
positive reaction against p26/p29 (TPI) was observed in the 
serum of a patient with an acute cytomegalovirus infection 
and a reactivated EBV  infection. 
After separation of the Raft cell lysate in preparative SDS 
gels, a sufficient amount of purified p26 could be gained by 
electroelution. Due to NH2-terminal blocking, the protein 
identification of p26 by amino acid sequencing was not suc- 
cessful. After incomplete cleavage of p26 with V8 protease, 
the fragments were separated in SDS-18%  PAGE. Their reac- 
tion with the serum of patient with IM was tested by immu- 
noblot. As Fig. 2 A  demonstrates, a peptide of 15 kD (p15) 
gave  a  positive  reaction.  The  sequence  of  the  18  NH2- 
terminal amino acids of this p15 fragment was determined 
with a gasphase sequencer. The sequence of this peptide was 
compared with data of the protein sequence databases of the 
Martinsried Institute for Protein Sequences and the Protein 
Identification Resource (cf 2B). There was complete identity 
with a sequence part of human MnSOD (19). The NH2 ter- 
minus of the 15-kD  fragment starts with alanine in accor- 
dance with position 72 of MnSOD.  Next to it in position 
71 there is glutamic acid, the cleavage point of the V8 pro- 
tease. Because of its size, the 15-kD  fragment probably ex- 
tends to the glutamic acid in position 211, a further cleavage 
point of the V8 protease.  Thus, it is in accordance with the 
sequence  of MnSOD  (19). 
MnSOD was isolated from human liver tissue in order to 
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Figure  1.  Reaction  of sera from  four  patients  in the acute  phase  of  EBV 
infections on Raji cell lysate  after SDS-PAGE. (Immunoblot,  detection 
of IgM isotype); ma, molecular  mass marker. 
test whether anti-p26 antibodies from patients' sera recog- 
nize MnSOD. In native PAGE, the purified enzyme showed 
up at about 100 kD, as was demonstrated by silver staining 
in Fig. 3, lane a. Contaminations with other liver proteins 
were not detected. The protein of the 100-kD band was en- 
zymatically active (cf 3 b), and was recognized by the anti- 
bodies from patient's sera (cf 3 c). In the denaturating SDS- 
PAGE the monomers of the tetrameric MnSOD molecule 
were found at 26 kD (cf 3 d). This band is also recognized 
by the antibodies (cf 3  e). 
Antibodies against MnSOD were purified from the sera 
of four patients with IM. The concentration of the affinity 
purified antibodies was adjusted to 0.2 #g/ml. All of the four 
affinity  purified antibodies inhibited the activity of MnSOD 
as shown in Fig. 4. However, the inhibitory activity varied 
considerably.  Antibodies from patient no. 1 had the weakest 
effect, leading to a reduction of the enzyme activity from 
833.5  nkat/ml to 542 nkat/ml, which is a 35% inhibition. 
The strongest inhibition was obtained by the antibodies of 
patient no. 3; reaching 89% by reducing the enzyme activity 
to  91.5 nkat/ml  (cf 4).  With  71  and  57%  inhibition of 
MnSOD, the efficacy of antibodies from patient nos.  2 and 
4 was between the above mentioned. Patient no. 3, whose 
anti-MnSOD antibodies showed the strongest inhibitor ac- 
tivity, was suffering from a prolonged course of the illness 
with distinct hepatitis and splenomegaly.  Patient no. 2 had 
been admitted to hospital with a rash and suspected menin- 
gitis.  In the 32 patients investigated the IgM anti-MnSOD 
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Fig,,re  4.  Inhibition  of human MnSOD by affinity  purified  antibodies 
from sera of patients with acute EBV infection. 
Figure 2.  Identification  of p26. (A) Lane  1, Raji cell lysate (immuno- 
blot); lane  2, purified  p26 (immunoblot);  lane  3, plS-fragments  from  purified 
p26 after  V8 protease  cleavage  (immunostaining  and NH2-terminal  amino 
acid sequence). (B) Comparison of the NH2-terminal  amino acids of the 
p15 fragment  with human MnSOD. The arrows point to the location  of 
V8 protease  cleavage  and mark the p15-fragment;  one letter  code  was used. 
These sequence  data are available  from  EMBL/GenBank/DDBJ  under  ac- 
cession number Y00472. 
antibodies reached their maximum value with titers up to 
1:3,200  at the onset of symptoms of IM, and fell below the 
detection limit within 6-8 wk. Patients' recovery coincided 
with the fall of autoantibodies. 
Discussion 
In the course of IM, patients are producing a number of 
autoantibodies. Hitherto, only antibodies against the blood 
Figure 3.  Demonstration  of the serological  identity  of  p26 and MnSOD. 
Lanes a, b, and c, MnSOD from human liver after native PAGE (lane a, 
silver staining; lane b, demonstration  of the enzyme  activity;  lane  c, reac- 
tion with affinity  purified  IgM anti-p26 antibodies);  lanes d and e, MnSOD 
from  human liver  tissue  after  denaturating  SDS-PAGE  (lane  d, silver  staining; 
lane e, reaction with affinity purified IgM anti-p26 antibodies). 
1997 
group antigen "i" (20) and antibodies against TPI are known 
to be clinically significant (3). Both antibodies are respon- 
sible for hemolysis and hemolytic anemia, which is a serious 
complication of IM.  We assume that  the detection of au- 
toantibodies against p26 and the presented identification of 
p26 as MnSOD may contribute to the understanding of the 
immunopathogenesis of IM. 
MnSOD catalyzes the dismutation of the superoxide anion 
to hydrogen peroxide and molecular oxygen. Besides the in- 
tracellular presence of  MnSOD, the enzyme is found in human 
serum in high concentrations (21).  It protects capillary en- 
dothelial cells against the damaging effects of superoxide (22). 
The autoantibodies we detected in sera of patients with acute 
EBV  infection were  capable  of blocking  the  function  of 
MnSOD.  We suspect that  this harmful mechanism causes 
the common physical signs in IM patients, such as disturbed 
liver function, gelatinous appearance of the soft palate, supraor- 
bital edema,  and exanthema. The well-known biochemical 
and histopathological changes in the acute phase of EBV in- 
fections may be quoted' to sustain our hypothesis; most of 
the lytically or latently infected B cells perish due to the virus 
production or the immune reaction, which mainly takes place 
in the perivascular space, especially in lymphatic organs.  Due 
to the destruction of virus-infected lymphocytes, the high 
turnover of nucleotides leads to increased activity of the xan- 
thine oxidase, as was measured by an increased level of uric 
acid in sera of IM patients. The enhanced catabolism of pu- 
rine bases by the xanthine oxidase leads to an excessive produc- 
tion of oxygen radicals  (23).  If MnSOD is blocked by the 
autoantibody, the removal of oxygen radicals is inhibited. A 
rise of the oxygen radical concentration has been observed 
to lead to a physiological cascade resulting in leukocyte mar- 
gination and vascular  leakage (24).  In transgenic mice evi- 
dence was given that oxygen injury increased the permeability 
of capillary endothelium, whereas MnSOD had a protective 
influence (22).  Antibodies were able to suspend the action 
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SOD activity in the membrane ofNocardia asteroides by mono- 
clonal antibodies rendered the bacterium highly susceptible 
to the toxic superoxide radicals  (25). These observations are 
important in regard to our conception. 
High autoantibody titers against MnSOD were detectable 
in all patients with acute EBV infections, but not in patients 
with other acute herpesvirus infections or in healthy pro- 
bands. Only one patient with acute cytomegalovirus infec- 
tion showed a weak reaction to MnSOD. In vitro the inhibi- 
tory activity of the purified autoantibodies against MnSOD 
varied among individual patients. According to our data, a 
strong inhibitory activity may be connected with a severe 
clinical course of IM. Sufficient amounts of serum for affinity 
purification of anti-MnSOD antibodies necessary for the per- 
formance of the inhibiting assay, as well as detailed clinical 
data were, however, only available in few patients. Thus, a 
correlation between the activity of the anti-MnSOD  anti- 
bodies and the severity of the disease will have to be left to 
a future prospective study. 
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